Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2015 | Pages:
131 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2015', provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Acute Renal Failure (ARF) (Acute Kidney Injury) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Acute Renal Failure (ARF) (Acute Kidney Injury) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents
2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Acute Renal Failure (ARF) (Acute Kidney Injury) Overview 10 Therapeutics Development 11 Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview 11 Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis 12 Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics under Development by Companies 13 Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics under Investigation by Universities/Institutes 15 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Products Glance 16 Clinical Stage Products 16 Early Stage Products 17 Acute Renal Failure (ARF) (Acute Kidney Injury) - Products under Development by Companies 18 Acute Renal Failure (ARF) (Acute Kidney Injury) - Products under Investigation by Universities/Institutes 20 Acute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics Development 21 A1M Pharma AB 21 Adrenomed AG 22 Am-Pharma B.V. 23 Angion Biomedica Corp. 24 Bolder Biotechnology, Inc. 25 Cellmid Limited 26 Complexa, Inc. 27 DiaMedica Inc. 28 Digna Biotech, S.L. 29 DURECT Corporation 30 F. Hoffmann-La Roche Ltd. 31 G1 Therapeutics, Inc. 32 Hadasit Medical Research Services & Development Ltd 33 Kringle Pharma, Inc. 34 NephroGenex, Inc. 35 NeuroVive Pharmaceutical AB 36 Noorik Biopharmaceuticals AG 37 Nyken BV 38 Opsona Therapeutics Limited 39 Orion Oyj 40 ProMetic Life Sciences Inc. 41 Quark Pharmaceuticals, Inc. 42 STATegics, Inc. 43 Thrasos, Inc. 44 Torrent Pharmaceuticals Limited 45 Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Assessment 46 Assessment by Monotherapy Products 46 Assessment by Target 47 Assessment by Mechanism of Action 49 Assessment by Route of Administration 51 Assessment by Molecule Type 53 Drug Profiles 55 A1M-001 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 adrecizumab - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 BB-3 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 BBT-030 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 BBT-045 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 CAB-101 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Cardiotrophin-1 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Cell Therapy to Activate Wnt7b for Kidney Injury - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 CXA-10 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 cyclosporine - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 DM-199 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 DUR-928 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 HYPER-IL-6 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 KP-100IT - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 levosimendan - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 MTP-131 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 N-003 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 NYK-1341 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 OPN-305 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 PBI-4419 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 pyridoxamine dihydrochloride - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 QPI-1002 - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 R-190 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 Recombinant Human Alkaline Phosphatase - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 Recombinant Protein for Sepsis, Inflammatory bowel disease, Acute Kidney Injury, Acute radiation syndrome and Ischemic organ injury - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 RLS-003 - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 RO-6839328 - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 Small Molecule to Inhibit HDAC for Acute Kidney Injury - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 STSE-15 - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 THR-184 - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 TRC-160334 - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 Acute Renal Failure (ARF) (Acute Kidney Injury) - Recent Pipeline Updates 101 Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects 121 Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products 122 Acute Renal Failure (ARF) (Acute Kidney Injury) - Product Development Milestones 123 Featured News & Press Releases 123 Jul 07, 2015: Thrasos Completes Enrollment of Phase 2 THR-184 Clinical Study for Acute Kidney Injury 123 Jun 09, 2015: Angion Biomedica To Commence Phase 2 Clinical Trial of BB3 in Acute Kidney Injury 123 Mar 27, 2015: NephroGenex Announces Data on Acute Kidney Injury at National Kidney Foundation 2015 Spring Clinical Meetings 124 Feb 23, 2015: Opsona Therapeutics Patent issued in USA covering an antibody directed against Toll-like Receptor-2 (TLR-2) and the use and development thereof 125 Feb 18, 2015: Opsona Therapeutics Patent issued in US and EU covering the Opsona-developed antibody OPN-305, which is directed against Toll-like Receptor-2 (TLR-2) and the use and development thereof 125 Feb 02, 2015: DiaMedica to Expand Focus of DM199 Development into Acute Vascular Diseases 126 Jan 20, 2015: AM-Pharma starts Adaptive Phase II trial of recAP in Acute Kidney Injury 127 Dec 15, 2014: Complexa Initiates Phase 1B Study of CXA-10 in Acute Kidney Injury 127 Nov 13, 2014: AM-Pharma Presents Preclinical Data On Mode-Of-Action For RecAP In Acute Kidney Injury 128 Sep 16, 2014: Thrasos Announces Successful Formal Interim Analysis and Clinical Update for Phase 2 Study of THR-184 for Acute Kidney Injury 128 Appendix 130 Methodology 130 Coverage 130 Secondary Research 130 Primary Research 130 Expert Panel Validation 130 Contact Us 130 Disclaimer 131
List of Tables
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H2 2015 11 Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis, H2 2015 12 Number of Products under Development by Companies, H2 2015 14 Number of Products under Investigation by Universities/Institutes, H2 2015 15 Comparative Analysis by Clinical Stage Development, H2 2015 16 Comparative Analysis by Early Stage Development, H2 2015 17 Products under Development by Companies, H2 2015 18 Products under Development by Companies, H2 2015 (Contd..1) 19 Products under Investigation by Universities/Institutes, H2 2015 20 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by A1M Pharma AB, H2 2015 21 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Adrenomed AG, H2 2015 22 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Am-Pharma B.V., H2 2015 23 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Angion Biomedica Corp., H2 2015 24 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Bolder Biotechnology, Inc., H2 2015 25 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Cellmid Limited, H2 2015 26 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Complexa, Inc., H2 2015 27 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DiaMedica Inc., H2 2015 28 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Digna Biotech, S.L., H2 2015 29 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DURECT Corporation, H2 2015 30 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 31 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by G1 Therapeutics, Inc., H2 2015 32 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2015 33 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Kringle Pharma, Inc., H2 2015 34 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NephroGenex, Inc., H2 2015 35 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NeuroVive Pharmaceutical AB, H2 2015 36 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Noorik Biopharmaceuticals AG, H2 2015 37 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Nyken BV, H2 2015 38 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Opsona Therapeutics Limited, H2 2015 39 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Orion Oyj, H2 2015 40 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by ProMetic Life Sciences Inc., H2 2015 41 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Quark Pharmaceuticals, Inc., H2 2015 42 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by STATegics, Inc., H2 2015 43 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Thrasos, Inc., H2 2015 44 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Torrent Pharmaceuticals Limited, H2 2015 45 Assessment by Monotherapy Products, H2 2015 46 Number of Products by Stage and Target, H2 2015 48 Number of Products by Stage and Mechanism of Action, H2 2015 50 Number of Products by Stage and Route of Administration, H2 2015 52 Number of Products by Stage and Molecule Type, H2 2015 54 Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics - Recent Pipeline Updates, H2 2015 101 Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, H2 2015 121 Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products, H2 2015 122
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
